Additionally, a combinatorial treatment with an antisense STAT3 inhibitor, AZD-1950, and an anti-PD-L1 monoclonal antibody, durvalumab, has advanced to a phase II clinical trial which includes advanced refractory pancreatic cancer patients (NCT02983578) (Table 1), with minimal toxicity being reported [2]. This evidence concerns the gene CD274 and familial pancreatic carcinoma.